



ImmunoPET of urokinase plasminogen activator (uPA) system: broad applicability in cancer imaging

Yang, Dongzhi; Severin, Gregory; Dougherty, Casey A.; Chen, Daiqin; Mazar, Andrew P.; Hong, Hao

Published in:
Journal of Nuclear Medicine

Publication date:
2016

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):
Yang, D., Severin, G., Dougherty, C. A., Chen, D., Mazar, A. P., & Hong, H. (2016). ImmunoPET of urokinase plasminogen activator (uPA) system: broad applicability in cancer imaging. *Journal of Nuclear Medicine*, 57(s2), [390].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.


[Print this Page for Your Records](#)
[Close Window](#)
Control/Tracking Number: SNMMI-A-781-2016

Activity: Annual Meeting - Physician/Scientist/Pharmacist

Current Date/Time: 1/6/2016 9:22:16 AM

ImmunoPET of urokinase plasminogen activator (uPA) system: broad applicability in cancer imaging

Author Block: Dongzhi Yang¹, Gregory W. Severin², Casey A. Dougherty¹, Daiqin Chen¹, Andrew P. Mazar³, Hao Hong¹, ¹University of Michigan, Radiology, Ann Arbor, MI, ²Technical University of Denmark, Center for Nuclear Technologies, Roskilde, DENMARK, ³Northwestern University, Chemistry of Life Processes Institute, Evanston, IL.


Abstract:

OBJECTIVES: The urokinase plasminogen activator (uPA) system is a proteolytic system comprised of a serine protease (uPA), its cell surface receptor (uPAR), and an inhibitor for uPA (PAI-1). Mounting evidence has demonstrated that over-expression of uPA/uPAR can be found in a variety of cancer cells along with tumor-associated stromal cells, and their expression is closely associated with cancer progression and metastasis. The uPA system is almost undetectable in healthy, quiescent tissue making it an attractive target for cancer imaging/therapy. Our goal is to utilize the uPA system as a universal cancer detection marker and develop a positron emission tomography (PET) tracer for imaging of uPA/uPAR in various cancer types.

METHODS: A monoclonal antibody for uPA (named ATN-291) was produced, conjugated to p-isothiocyanatobenzyl-desferrioxamine (p-SCN-Bn-Df), and subsequently labeled with ⁸⁹Zr. Competitive binding assay, flow cytometry and confocal microscopic studies were performed in cancer cell lines with different uPA expression levels (high: U87MG, low: LNCaP). PET imaging, biodistribution, histological examination and Western Blot were performed in mouse xenografts bearing different types of tumors (glioma, breast, prostate, pancreatic, and ovarian) to evaluate the capacity and specificity of ⁸⁹Zr-Df-ATN-291 to target uPA in vivo.

RESULTS: Binding assay and FACS analyses in U87MG and LNCaP cells revealed similar uPA binding affinity/specificity (in the nanomolar range) between ATN-291 and Df-ATN-291, which was further validated by fluorescence microscopy. ⁸⁹Zr-labeling was achieved with high yield and specific activity. PET imaging revealed that uptake of ⁸⁹Zr-Df-ATN-291 could delineate U87MG tumors (high uPA) as early as 2 h post-injection, and the tumor accumulation was very persistent (34.1±2.3%ID/g at 120 h p.i. with a tumor-to-muscle ratio of 45.2±9.0, n = 4) while its uptake in LNCaP (low uPA) was significantly lower (<8%ID/g at each time point, n = 3). Accumulation of ⁸⁹Zr-Df-ATN-291 in MDA-MB-231, PC-3, BXP-3, and SKOV-3 tumors was also detected by PET and validated by organ distribution via gamma counting. Interestingly, both Western Blot and histology studies showed strong correlations between uPA+uPAR expression (rather than sole uPA expression) in these tumor tissues and tumor uptake of ⁸⁹Zr-Df-ATN-291.

CONCLUSION: Successful PET imaging of the uPA system with ⁸⁹Zr-Df-ATN-291 in different tumor types confirms its value in cancer diagnosis and envisages the



potential of this novel antibody for targeted radiotherapy and detection of cancer.

Presentation Preference (Complete): Oral or Poster

Category Selection (Complete): Preclinical Probes for Oncology

FDA Disclosure/Additional Information (Complete):

: No

Awards (Complete):

Cardiovascular YIA Symposium: No

Brain Imaging Council (Neurosciences) YIA Symposium: No

Computer and Instrumentation Council YIA Symposium: No

Radiopharmaceutical Sciences Council (RPSC) YIA Symposium: Yes

Center for Molecular Imaging Innovation & Translation (CMIIT) YIA Symposium: Yes

Nuclear Oncology YIA Symposium: No

Berson-Yalow Award: Yes

Correlative Imaging Council Walter Wolf YIA: Yes

Young Professional Committee (YPC) Award: Yes

Awards Cont. (Complete):

Pediatrics Council YIA: No

Art Weis Award: No

Masahiro Iio, MD Award: No

Payment (Complete): Your credit card order has been processed on Wednesday 6 January 2016 at 9:18 AM.

Attached Files:

No Files Attached

Status: Complete

[Leave OASIS Feedback](#)

Powered by [OASIS](#), The Online Abstract Submission and Invitation System SM

© 1996 - 2016 [Coe-Truman Technologies, Inc.](#) All rights reserved.